An Obscure Drug Discount Program Stifles Use of Federal Lifeline by Rural Hospitals
A disconnect between two federal programs meant to help keep hospitals afloat discourages struggling rural facilities from accepting the aid.
The independent source for health policy research, polling, and news.
161-180 of 1,318 results
A disconnect between two federal programs meant to help keep hospitals afloat discourages struggling rural facilities from accepting the aid.
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
KFF Health News and California Healthline staffers made the rounds on national and local media in the last couple of weeks to discuss topical stories. Here’s a collection of their appearances.
As billions of dollars from settlements with opioid manufacturers and distributors go to state and local governments, efforts to reduce the epidemic’s harm can be hamstrung by drug paraphernalia laws. Health authorities say distributing clean syringes to users can save lives, but in states like Pennsylvania, it may be illegal.
A decade after Congress told the FDA to expedite the approval of more effective sunscreens, the federal government still has not approved sunscreen ingredients that are safely being used around the world. Meanwhile, skin cancer is the nation’s most common cancer.
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
A six-week abortion ban took effect in Florida this week, dramatically restricting access to the procedure not just in the nation’s third-most-populous state but across the South. Patients from states with even more restrictive bans had been flooding in since the overturn of Roe v. Wade in 2022. Meanwhile, the CEO of the health behemoth UnitedHealth Group appeared before committees in both the House and Senate, where lawmakers grilled him about the February cyberattack on subsidiary Change Healthcare and how its ramifications are being felt months later. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachana Pradhan of KFF Health News join KFF Health News’ Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
KFF Health News and California Healthline staff made the rounds on national and local media over the past two weeks to discuss recent stories. Here’s a collection of their appearances.
KFF Health News staff made the rounds on state and local media in recent weeks to discuss stories they and their colleagues reported. Here’s a collection of their appearances.
Researchers at the University of Montana have pitched in to develop a more effective vaccine in the fight against an ancient disease that still kills an estimated 1.6 million people a year worldwide.
Facing widening racial disparities in overdose deaths, Philadelphia officials are sending workers and volunteers to knock on doors across the city, aiming to equip households with naloxone and other drug overdose prevention supplies. City officials hope a proactive approach will normalize naloxone as an everyday item in people’s medicine cabinets and prevent overdoses, especially among Black residents.
KFF Health News gives readers a chance to comment on a recent batch of stories.
Most of the doctors the FDA tapped to advise it on an Abbott medical device had financial ties to the company. The FDA didn’t disclose the payments.
Most Medicare enrollees likely were not paying a monthly average of $400 — as President Joe Biden stated — before the insulin cap took effect. However, because costs and other factors result in widely varying prices, some Medicare enrollees might have paid that much in a given month.
The Supreme Court this week heard its first abortion case since overturning Roe v. Wade in 2022, about an appeals court ruling that would dramatically restrict the availability of the abortion pill mifepristone. But while it seems likely that this case could be dismissed on a technicality, abortion opponents have more challenges in the pipeline. Meanwhile, health issues are heating up on the campaign trail, as Republicans continue to take aim at Medicare, Medicaid, and the Affordable Care Act — all things Democrats are delighted to defend. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Lauren Weber of The Washington Post join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Tony Leys, who wrote a KFF Health News-NPR “Bill of the Month” feature about Medicare and a very expensive air-ambulance ride. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
The end goal for a conservative Christian group’s mifepristone case before the Supreme Court: a de facto nationwide abortion ban.
For years, addiction response teams have traveled around Florida to connect people who have overdosed with resources and recovery centers. Now, a handful have a new tool in their kit: buprenorphine, which can help prevent the cravings and withdrawal symptoms that lead to more drug use.
KFF Health News and California Healthline staff made the rounds on national and local media in recent weeks to discuss their stories. Here’s a collection of their appearances.
© 2026 KFF